Left atrial appendage closure or anticoagulation for atrial fibrillation (Registro nro. 22833)
[ vista simple ]
| 000 -Cabecera | |
|---|---|
| Campo de control interno | 03414nam a2200373 4500 |
| 001 - Número de control | |
| control field | ESSALUD |
| 005 - Fecha y hora de la última transacción | |
| Campo de control | 20260819163736.0 |
| 007 - Tipo material - Descripcion fisica - info general | |
| Tipo material - Descripcion fisica - info general | ta |
| 008 - Elementos de Longitud Fija - Información General | |
| Elementos de Longitud Fija - Información | t pe ||||| |||| 00| 0 spa d |
| 040 ## - Origen de la Catalogación | |
| Origen de la Catalogación | BMG |
| 041 ## - Idioma | |
| Idioma | eng |
| 100 ## - Autor | |
| Autor | Doshi, Shephal K. |
| Rol del Autor | Autor |
| 9 (RLIN) | 54162 |
| 245 ## - Titulo | |
| Titulo | Left atrial appendage closure or anticoagulation for atrial fibrillation |
| 300 ## - Páginas | |
| Paginación | páginas: 2083-2094 |
| 520 ## - Resumen | |
| Resumen | Background: For patients with atrial fibrillation, the use of oral anticoagulant therapy to prevent stroke is limited by the risk of bleeding. Left atrial appendage closure is considered for patients who are unsuitable candidates for long-term anticoagulation, but its role in patients who are eligible for anticoagulants has not been established. Methods: In this ongoing, prospective, international, randomized trial involving patients with atrial fibrillation who were suitable candidates for anticoagulation, we randomly assigned patients in a 1:1 ratio to receive either device-based left atrial appendage closure (device group) or non–vitamin K antagonist oral anticoagulant (NOAC) therapy (anticoagulation group). The primary efficacy end point — a composite of death from cardiovascular causes, stroke, or systemic embolism — was tested for noninferiority (noninferiority margin, 4.8 percentage points) after 3 years of follow-up. The primary safety end point, non–procedure-related bleeding, was tested for superiority. Results: Of the 3000 patients who underwent randomization, 1499 were assigned to the device group and 1501 to the anticoagulation group. The mean (±SD) age of the patients was 71.7±7.5 years, 31.9% of the patients were women, and the mean CHA2DS2-VASc score was 3.5±1.3. At 3 years, a primary efficacy end-point event had occurred in 81 patients (Kaplan–Meier estimate, 5.7%) in the device group and in 65 patients (Kaplan–Meier estimate, 4.8%) in the anticoagulation group (difference, 0.9 percentage points; 95% confidence interval [CI], −0.8 to 2.6; P<0.001 for noninferiority). Non–procedure-related bleeding occurred in 154 patients (Kaplan–Meier estimate, 10.9%) in the device group and in 260 patients (Kaplan–Meier estimate, 19.0%) in the anticoagulation group (hazard ratio, 0.55; 95% CI, 0.45 to 0.67; P<0.001 for superiority). Conclusions: Among patients with atrial fibrillation who were candidates for anticoagulation, device-based left atrial appendage closure was noninferior to NOAC therapy with respect to a composite of death from cardiovascular causes, stroke, or systemic embolism and was superior to NOAC therapy for non–procedure-related bleeding at 3 years. |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | ANTICOAGULACIÓN |
| 9 (RLIN) | 53834 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | TROMBOEMBOLISMO |
| 9 (RLIN) | 32218 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | ARRITMIAS |
| 9 (RLIN) | 53863 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | CARDIOLOGÍA |
| 9 (RLIN) | 11301 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | MARCAPASOS |
| 9 (RLIN) | 53864 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | DESFIBRILADORES |
| 9 (RLIN) | 53865 |
| 700 ## - Autor Personal | |
| Autor Personal | Kar, Saibal |
| 9 (RLIN) | 54163 |
| 700 ## - Autor Personal | |
| Autor Personal | Nair, Devi G. |
| 9 (RLIN) | 53867 |
| 700 ## - Autor Personal | |
| Autor Personal | Waggoner, Thomas |
| 9 (RLIN) | 54164 |
| 700 ## - Autor Personal | |
| Autor Personal | Agarwal, Himanshu |
| 9 (RLIN) | 54165 |
| 700 ## - Autor Personal | |
| Autor Personal | Moussavian, Mehran |
| 9 (RLIN) | 54166 |
| 700 ## - Autor Personal | |
| Autor Personal | Kashani, Amir |
| 9 (RLIN) | 54167 |
| 700 ## - Autor Personal | |
| Autor Personal | Oza, Saumil |
| 9 (RLIN) | 54168 |
| 700 ## - Autor Personal | |
| Autor Personal | Feldman, Leon |
| 9 (RLIN) | 54169 |
| 700 ## - Autor Personal | |
| Autor Personal | Sadhu, Ashish |
| 9 (RLIN) | 54170 |
| 700 ## - Autor Personal | |
| Autor Personal | DeLurgio, David |
| 9 (RLIN) | 54171 |
| 773 0# - Revista (Relacion con el numero) | |
| Host Biblionumber | 22717 |
| Host Itemnumber | 22648 |
| Ciudad, Editorial | Massachusetts NEJM Group |
| Codigo barras item/ejemplar | NEJM011 |
| Titulo de la Revista | The New England Journal of Medicine |
| Número de control de registro | ESSALUD |
| ISSN | 0028-4793 |
| 942 ## - Elementos de Koha | |
| Tipo de Documento | Artículos |
| Fecha procesamiento | 2026-08-19 |
| Catalogador | sqb |
No hay ítems disponibles.